GK activator 2 + simvastatin

**GK activator 2 + simvastatin** is a combination drug therapy consisting of a glucokinase (GK) activator (specifically "GK activator 2", a small molecule that enhances the activity of glucokinase, a key enzyme regulating glucose metabolism) and **simvastatin**, an HMG-CoA reductase inhibitor widely used to lower cholesterol and reduce cardiovascular risk. GK activators aim to improve glucose homeostasis, primarily investigated for type 2 diabetes and metabolic disorders, by increasing hepatic and pancreatic glucokinase activity to lower blood glucose levels. Simvastatin, derived from Aspergillus terreus, competitively inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and upregulating hepatic LDL receptors to lower plasma LDL and VLDL levels[3]. While simvastatin is approved for hyperlipidemia and cardiovascular risk reduction[3], GK activator 2 is an investigational agent, primarily in preclinical or early-stage clinical research. Recent studies suggest statins and GK activators may have synergistic or additive effects on metabolic pathways, including inhibition of SREBP2 maturation and modulation of glucose and lipid metabolism, but GK activator + statin combinations are not currently approved for any indication[1].

Other names

GK activator 2simvastatin